ENLV – enlivex therapeutics ltd. - ordinary shares (US:NASDAQ)
Stock Stats
News
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis [Yahoo! Finance]
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]
Form 6-K Enlivex Therapeutics For: Dec 11
Form 6-K Enlivex Therapeutics For: Dec 03
Form 6-K Enlivex Therapeutics For: Nov 29
Form 6-K Enlivex Therapeutics For: Nov 20
Form SC 13G Enlivex Therapeutics Filed by: ARMISTICE CAPITAL, LLC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.